NCT03194555已完成2 期
Randomized, Double-Blind, Study to Assess Low-Dose Naltrexone and Acetaminophen Combination in the Prevention of Episodic Migraine in Adults
Allodynic Therapeutics, Inc1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2017年8月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.
研究概览
简要总结
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is a male or a female 18 years of age or older.
- •History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with onset of migraine prior to 50 years of age.
- •Migraine-associated nausea with ≥half of migraine attacks.
- •5-8 migraine/probable migraine headache days on average per month in the three months prior to Visit 1 and during the Baseline Period.
- •The patient agrees to refrain from taking opiate medications from Visit 1 to 7 days after the last dose of the study drug.
- •The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA.
- •The patient has been taking a stable dose of a medication with migraine prevention potential for at least 3 month prior to the screening visit and agrees to not start, stop, or change dosage of any medication with migraine prevention potential during the study period. (E.g., beta-blockers, calcium channel blockers, tricyclic antidepressants, anticonvulsants, selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine re-uptake inhibitors (SNRIs), magnesium or riboflavin supplements at high doses, herbal preparations (e.g. feverfew or St. john's wort)), Botulinum toxin must be discontinued one year prior to Visit
- •The patient agrees to forgo any elective surgery for the duration of the study.
- •The female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using 2 methods of adequate and reliable contraception throughout the study and for 28 days after taking the last dose of the study drug (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.
排除标准
- •Usage of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) ≥15 days/month, or ergotamine and triptans >10 days/month, or opioids and barbiturates >2 days/month in the 3 months prior to Visit 1 or during the Baseline Period.
- •Tension-type-like, and/or migraine-like headache on ≥15 days per month in the 3 months prior to Visit 1 or during the Baseline Period. Diagnosis of chronic migraine, cluster headache or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic migraine).
- •Regular use of the following medications for any reason: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antipsychotic drugs, monoamine oxidase inhibitors, benzodiazepines, sleep medications, muscle relaxants, anti-emetic medications, blood thinning medications (e.g., warfarin or heparin), cannabinoids, or botulinum toxin to head and neck regions. Low-dose aspirin for cardiovascular disease prophylaxis is permitted.
- •Confounding painful conditions, (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome, etc.).
- •Diagnosis of any concurrent medical or psychiatric condition; this includes, chronic unstable debilitating diseases such as Parkinson's disease, multiple sclerosis, cancer, significant renal impairment, significant hepatic impairment, etc.
- •The patient has a history or diagnosis of moderate-to-severe hepatic or renal impairment (>2 × the upper limit of normal [ULN] for alanine transaminase or aspartate transaminase. ≥1.5 × ULN for alkaline Phosphatase, bilirubin, BUN, or creatinine). (Patients with elevated bilirubin level due to Gilbert's syndrome are allowed).
- •The patient has a history within the previous 5 years of abuse of any drug, prescription, illicit, or alcohol.
- •The Female patient is pregnant, actively trying to become pregnant, or breast-feeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
- •The patient has known-allergy to any of the components of the investigational drug.
- •Participation in another study with an investigational drug within 30 days before Visit 1 or during the study.
- •Use of emergency care treatment more than 3 times in the previous 6 months.
- •The patient is in the opinion of the investigator, is unsuitable to participate in this study for any other reason.
研究组 & 干预措施
Low-Dose Naltrexone and Acetaminophen Combination
Experimental
干预措施: Low-Dose Naltrexone and Acetaminophen Combination (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.
时间窗: From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.
Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version). Migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).
次要结局
- The Change in HIT-6 From Baseline to Last 28 Days of Treatment(From the 28-day baseline period to the last 28 days of the 84-day treatment period.)
- The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.(From the 28-day baseline period to the last 28 days of the 84-day treatment period.)
- The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)(From the28-day baseline period to the last 28 days of the 84-day treatment period.)
- Mean Monthly Acute Migraine Medication Treatment Days Change From Baseline to Last 28 Days of Treatment(From the 28-day baseline period to the last 28 days of the 84-day treatment period.)
- The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)(From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With NauseaMigraine With and Without AuraNCT03185143Allodynic Therapeutics, Inc36
已完成
2 期
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of MigraineMigraine With or Without AuraNCT03061734Allodynic Therapeutics, Inc92
已完成
2 期
An Acute Migraine Factorial StudyMigraine With or Without AuraNCT06245902Allodynic Therapeutics, Inc92
已完成
2 期
Low-dose Naltrexone for Post-COVID Fatigue SyndromePost-Viral Fatigue SyndromeNCT05430152Luis Nacul160
已完成
不适用
Adjunctive Treatment of Chronic Migraine Using an Oral Dental DeviceChronic Migraine, HeadacheNCT04871581ChairsideSplint.com25